Trials / Withdrawn
WithdrawnNCT04041362
the Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients
A Phase II, Open-label, Controlled, Proof-of-concept Study to Evaluate the Safety of UB-421 in Combination With Antiretroviral Therapy (ART) and the Efficacy in Reduction of HIV Viral Load and Proviral DNA as Compared to ART Alone in ART-experienced Viremic HIV-1 Patients
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- United BioPharma · Industry
- Sex
- All
- Age
- 20 Years – 100 Years
- Healthy volunteers
- Not accepted
Summary
This study assess the safety, tolerability, and efficacy in reducing viral load and proviral DNA of UB-421 administered as an add-on to the ART in ART-experienced viremic HIV-1 subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | UB-421 | Monoclonal antibody by IV infusion plus standard ART |
| OTHER | Antiretroviral Therapy (ART) | Standard ART |
Timeline
- Start date
- 2020-04-01
- Primary completion
- 2020-12-01
- Completion
- 2021-03-01
- First posted
- 2019-08-01
- Last updated
- 2020-02-21
Source: ClinicalTrials.gov record NCT04041362. Inclusion in this directory is not an endorsement.